Stockreport

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses ---- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per [Read more]